Cardiotoxicity induced by the combination therapy of chloroquine and azithromycin in human embryonic stem cell-derived cardiomyocytes

키워드

참고문헌 (40)

1. Savarino A, "Effects of chloroquine on viral infections: an old drug against today's diseases?", Lancet Infect Dis, 3, pp.722~727 (2003)
2. Savarino A, "New insights into the antiviral effects of chloroquine", Lancet Infect Dis, 6, pp.67~69 (2006)
3. Vincent MJ, "Chloroquine is a potent inhibitor of SARS coronavirus infection and spread", Virol J, 2, pp.69~ (2005)
4. Wang M, "Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus(2019-nCoV)in vitro", Cell Res, 30, pp.269~271 (2020)
5. Yao X, "In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2(SARS-CoV-2)", Clin Infect Dis, 71, pp.732~739 (2020)
6. Gautret P, "Hydroxychloroquine and azithromycin as a treatment of COVID-19 : results of an open-label non-randomized clinical trial", Int J Antimicrob Agents, 56, pp.105949~ (2020)
7. Colson P, "Chloroquine for the 2019 novel coronavirus SARS-CoV-2", Int J Antimicrob Agents, 55, pp.105923~ (2020)
8. Satarker S, "Hydroxychloroquine in COVID-19 : Potential mechanism of action against SARS-CoV-2", Curr Pharmacol Rep, 6, pp.203~211 (2020)
9. Das S, "An Updated Systematic Review of the Therapeutic Role of Hydroxychloroquine in Coronavirus Disease-19(COVID-19)", Clin Drug Investig, 40, pp.591~601 (2020)
10. Pillat MM, "Insights in chloroquine action : perspectives and implications in Malaria and COVID-19", Cytometry A, 97, pp.872~881 (2020)
11. Boulware DR, "A Randomized Trial of Hydroxychloroquine as Postexposure Prophylaxis for Covid-19", N Engl J Med, 383, pp.517~525 (2020)
12. Chatre C, "Cardiac Complications Attributed to Chloroquine and Hydroxychloroquine : A Systematic Review of the Literature", Drug Saf, 41, pp.919~931 (2018)
13. White NJ, "Cardiotoxicity of antimalarial drugs", Lancet Infect Dis, 7, pp.549~558 (2007)
14. Min JY, "Macrolide therapy in respiratory viral infections", Mediators Inflamm, 2012, pp.649570~ (2012)
15. Tran DH, "Azithromycin, a 15-membered macrolide antibiotic, inhibits influenza A(H1N1)pdm09 virus infection by interfering with virus internalization process", J Antibiot(Tokyo), 72, pp.759~768 (2019)
16. Scherrmann JM, "Intracellular ABCB1 as a Possible Mechanism to Explain the Synergistic Effect of Hydroxychloroquine-Azithromycin Combination in COVID-19Therapy", AAPS J, 22, pp.86~ (2020)
17. Ohe M, "Macrolide treatment for COVID-19: Will this be the way forward?", Biosci Trends, 14, pp.159~160 (2020)
18. Chorin E, "The QT interval in patients with COVID-19 treated with hydroxychloroquine and azithromycin", Nat Med, 26, pp.808~809 (2020)
19. Ramireddy A, "Experience With Hydroxychloroquine and Azithromycin in the Coronavirus Disease 2019 Pandemic : Implications for QT Interval Monitoring", J Am Heart Assoc, 9, pp.e017144~ (2020)
20. Juurlink DN, "The cardiovascular safety of azithromycin", CMAJ, 186, pp.1127~1128 (2014)
21. Mitra RL, "An algorithm for managing QT prolongation in coronavirus disease 2019(COVID-19)patients treated with either chloroquine or hydroxychloroquine in conjunction with azithromycin : Possible benefits of intravenous lidocaine", Heart Rhythm Case Rep, 6, pp.244~248 (2020)
22. Ray WA, "Azithromycin and the risk of cardiovascular death", N Engl J Med, 366, pp.1881~1890 (2012)
23. Juurlink DN, "Safety considerations with chloroquine, hydroxychloroquine and azithromycin in the management of SARS-CoV-2 infection", CMAJ, 192, pp.E450~E453 (2020)
24. Gintant G, "Evolution of strategies to improve preclinical cardiac safety testing", Nat Rev Drug Discov, 15, pp.457~471 (2016)
25. Satsuka A, "Cardiotoxicity Assessment of Drugs Using Human iPS Cell-Derived Cardiomyocytes : Toward Proarrhythmic Risk and Cardio-Oncology", Curr Pharm Biotechnol, 21, pp.765~772 (2020)
26. Sharma A, "Use of human induced pluripotent stem cell-derived cardiomyocytes to assess drug cardiotoxicity", Nat Protoc, 13, pp.3018~3041 (2018)
27. Thomson JA, "Embryonic stem cell lines derived from human blastocysts", Science, 282, pp.1145~1147 (1998)
28. Cheng DK, "Nonuniform responses of transmembrane potential during electric field stimulation of single cardiac cells", Am J Physiol, 277, pp.H351~362 (1999)
29. Rast G, "An integrated platform for simultaneous multiwell field potential recording and Fura-2-based calcium transient ratiometry in human induced pluripotent stem cell(hiPSC)-derived cardiomyocytes", J Pharmacol Toxicol Methods, 75, pp.91~100 (2015)
30. Inciardi RM, "Cardiac Involvement in a Patient With Coronavirus Disease 2019(COVID-19)", JAMA Cardiol, 5, pp.819~824 (2020)
31. Sala S, "Acute myocarditis presenting as a reverse Tako-Tsubo syndrome in a patient with SARS-CoV-2 respiratory infection", Eur Heart J, 41, pp.1861~1862 (2020)
32. Tavazzi G, "Myocardial localization of coronavirus in COVID-19cardiogenic shock", Eur J Heart Fail, 22, pp.911~915 (2020)
33. Sirenko O, "Multiparameter in vitro assessment of compound effects on cardiomyocyte physiology using iPSC cells", J Biomol Screen, 18, pp.39~53 (2013)
34. Traebert M, "Inhibition of hERG K+ currents by antimalarial drugs in stably transfected HEK293 cells", Eur J Pharmacol, 484, pp.41~48 (2004)
35. Mubagwa K, "Cardiac effects and toxicity of chloroquine : a short update", Int J Antimicrob Agents, 56, pp.106057~ (2020)
36. Vicente J, "Assessment of Multi-Ion Channel Block in a Phase I Randomized Study Design : Results of the CiPA Phase I ECG Biomarker Validation Study", Clin Pharmacol Ther, 105, pp.943~953 (2019)
37. Haeusler IL, "The arrhythmogenic cardiotoxicity of the quinoline and structurally related antimalarial drugs : a systematic review", BMC Med, 16, pp.200~ (2018)
38. Lian X, "Directed cardiomyocyte differentiation from human pluripotent stem cells by modulating Wnt", beta-catenin signaling under fully defined conditions, 2013, pp.8, 162~175
39. Lian X, "Robust cardiomyocyte differentiation from human pluripotent stem cells via temporal modulation of canonical Wnt signaling", Proc Natl Acad Sci U S A, 109, pp.E1848~1857 (2012)
40. Tohyama S, "Distinct metabolic flow enables large-scale purification of mouse and human pluripotent stem cell-derived cardiomyocytes", Cell Stem Cell, 12, pp.127~137 (2013)

관련 논문AI추천